Zeto Inc Boosts Visibility in Point-of-Care EEG With ACNS Conference Push

Zeto Inc, a neurodiagnostics company focused on modernizing electroencephalography in clinical settings, used the week to deepen its role in the emerging point-of-care and rapid EEG market. The company highlighted both its participation and subsequent clinical discussions at the American Clinical Neurophysiology Society Annual Meeting.

Zeto joined the meeting’s inaugural Innovative Technology Lab, a forum dedicated to point-of-care EEG solutions that convened clinicians and industry stakeholders. CEO Florian Strelzyk presented on clinical needs, evidence, limitations, and implementation challenges related to rapid EEG deployment.

The company also showcased its Zeto ONE platform, described as a full-montage EEG system designed for critical care and other high-acuity hospital environments. Messaging emphasized workflow efficiency and clinical utility as key differentiators aimed at improving adoption in neurology and critical care settings.

Beyond the technology lab, Zeto maintained a presence on the exhibition floor to engage neurologists, hospital decision-makers, and key opinion leaders. This mix of scientific dialogue and traditional conference marketing is intended to raise brand visibility and refine product-market fit for its EEG technologies.

No new financial metrics, formal partnerships, or commercialization milestones were disclosed during the week. However, the company’s emphasis on evidence-based discussion and real-world implementation barriers suggests a continued focus on clinical credibility and integration into hospital workflows.

If these efforts translate into product refinements and stronger clinical validation, Zeto could improve its competitive positioning in the neurodiagnostics market over time. Overall, the week represented a visibility and relationship-building milestone as the company advances its strategy in point-of-care and rapid EEG.